
Seers, a wearable artificial intelligence (AI) diagnostic monitoring company, said Thursday that it has been selected as a newly included stock in Korea Exchange’s “KOSDAQ 150” index.
Following its inclusion in the KRX300 in May and the KRX Healthcare Index in September, Seers has now secured a place in three major representative and sector indices as a domestic medical AI company.
Korea Exchange announced the results of the regular revision for major stock indices, including the KOSDAQ 150, on the 18th. In this regular revision, a total of 16 stocks, including Seers, were newly included in the KOSDAQ 150, with Seers being the only specialized medical AI diagnostic and monitoring company among them. The revised index composition will take effect from December 11.
In May, Seers became the first domestic medical AI company to be included in the KRX300 index, which covers both the Korea Exchange (KOSPI) and KOSDAQ markets.
Subsequently, in September, it was listed as the only medical AI company among the constituent stocks of the KRX Healthcare Index, which represents the domestic healthcare industry.
The industry anticipates that interest will grow in companies possessing market representativeness and business competitiveness, given that the government and Korea Exchange are promoting the introduction of a “promotion/demotion segment system” to separately classify high-quality companies for the purpose of strengthening the competitiveness of the KOSDAQ market.
Seers plans to enhance its market recognition through inclusion in major indices while responding to future changes in market systems by strengthening medium- and long-term business performance and financial competitiveness.

Seers is conducting its medical AI business based on its AI inpatient monitoring platform, “thynC™,” and its wearable AI electrocardiogram (ECG) analysis solution, “mobiCARE™.” While expanding its patient monitoring business centered on domestic hospitals, it is also pursuing entry into global medical markets, including the United Arab Emirates (UAE) and Vietnam, based on approval from the U.S. Food and Drug Administration (FDA).
Earlier this month, Seers announced that it signed an MOU with VPS Healthcare Holdings, a major UAE medical investment group, to build AI smart wards and cardiac diagnostic centers, and that it would proceed with constructing thynC-based AI smart wards and mobiCARE-based cardiac diagnostic centers at key private hospitals locally.
A company official stated, “Through consecutive inclusion in major representative and sector indices, we have expanded our market representativeness as a medical AI company,” adding, “Going forward, we will strengthen the business competitiveness of thynC and mobiCARE and accumulate substantial business results in domestic and international markets to increase corporate valuation.”